10.28.26 -- What Thirty Years Of EBVST Teaches Us About Off-The-Shelf Cell Therapy

Outsourced gene therapy programs need integrated, real-time visibility across CDMO networks to improve governance, accelerate decisions, manage risk, and strengthen delivery.

Obesity is a hot topic in the pharmaceutical industry, with GLP-1 drugs dominating the headlines. Globally, there are 5,189 obesity trials, of which 1,119 are planned or ongoing.

Participant support can expand trial access, but regulatory uncertainty limits adoption. A safe harbor could enable reimbursement and compensation while protecting against coercion and undue influence.

Retention, body composition, maintenance therapy, amylin combinations, and behavioral support are reshaping obesity trials. Learn how sponsors can reduce dropout risk and strengthen clinical data.

Discover how solutions driven by artificial intelligence can enhance compliance, optimize workflows, and drive efficiency in biopharma operations.

Let's take a look at where continuous, real-time regulatory review can meaningfully speed drug development, and where it likely won't help much.